This case reinforces the importance of an individualized approach to follow-up and management in spinal meningiomas, ensuring that both tumor behavior and differential diagnostic considerations are carefully evaluated. In this case, no molecular profiling (e.g., TRAF7, KLF4, SMO, or NF2 mutation testing) was performed. The gene discussed is NF2; the disease is meningioma.